Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab
- PMID: 11277182
- DOI: 10.1038/sj.bmt.1702792
Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab
Abstract
Management of monoclonal lymphoproliferative disease following stem cell transplantation is difficult and previous attempts to eradicate tumor using chemotherapy or radiation therapy alone have not been successful. We report successful early eradication of an EBV negative, B cell non-Hodgkin's lymphoma in a child who received a T cell-depleted, maternal haploidentical bone marrow transplant for severe combined immunodeficiency disease. Our treatment strategy involved combining conventional induction chemotherapy with re-transplantation using the paternal donor as a source of peripheral blood stem cells, followed by treatment with anti-CD 20 monoclonal antibody (Rituximab). This strategy exploits the potential graft-versus-tumor activity of the mature T cells in the graft, while providing a source of stem cells to confer long-term immune function. The administration of Rituximab in the early post-transplant course may provide additional anti-tumor activity without affecting the new stem cell compartment.
Similar articles
-
Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma.Pediatr Hematol Oncol. 2006 Jan-Feb;23(1):19-24. doi: 10.1080/08880010500313280. Pediatr Hematol Oncol. 2006. PMID: 16326408
-
Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.Bone Marrow Transplant. 2003 May;31(9):775-82. doi: 10.1038/sj.bmt.1703925. Bone Marrow Transplant. 2003. PMID: 12732884 Clinical Trial.
-
Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.Eur J Haematol Suppl. 2001 Jul;64:56-62. Eur J Haematol Suppl. 2001. PMID: 11486404 Clinical Trial.
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
-
Haploidentical bone marrow stem cell transplantation in human severe combined immunodeficiency.Semin Hematol. 1993 Oct;30(4 Suppl 4):92-101; discussion 102-4. Semin Hematol. 1993. PMID: 7905667 Review.
Cited by
-
Treatment with rituximab in benign and malignant hematologic disorders in children.J Pediatr. 2007 Apr;150(4):338-44, 344.e1. doi: 10.1016/j.jpeds.2006.12.038. J Pediatr. 2007. PMID: 17382107 Free PMC article. Review. No abstract available.
-
Immunotherapy for epstein-barr virus-related lymphomas.Mediterr J Hematol Infect Dis. 2009 Nov 17;1(2):e2009010. doi: 10.4084/MJHID.2009.010. Mediterr J Hematol Infect Dis. 2009. PMID: 21416001 Free PMC article.
-
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future.Pharmaceuticals (Basel). 2016 May 19;9(2):28. doi: 10.3390/ph9020028. Pharmaceuticals (Basel). 2016. PMID: 27213405 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
